A
Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
XETRA:APPH
Price:
11
EUR
Market Closed
Market Cap:
€93.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Apontis Pharma AG
XETRA:APPH
|
DE |
Balance Sheet
Balance Sheet Decomposition
Apontis Pharma AG
Apontis Pharma AG
Balance Sheet Decomposition is not available for
Apontis Pharma AG
Apontis Pharma AG
Balance Sheet
Apontis Pharma AG
Apontis Pharma AG
Currency: EUR
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
7
|
8
|
30
|
36
|
27
|
15
|
|
| Cash |
7
|
8
|
30
|
36
|
27
|
15
|
|
| Total Receivables |
1
|
1
|
3
|
2
|
1
|
0
|
|
| Accounts Receivables |
1
|
1
|
3
|
2
|
1
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
4
|
3
|
5
|
3
|
6
|
5
|
|
| Other Current Assets |
1
|
0
|
1
|
0
|
1
|
2
|
|
| Total Current Assets |
13
|
13
|
38
|
42
|
35
|
23
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
1
|
1
|
1
|
|
| Intangible Assets |
16
|
15
|
15
|
16
|
18
|
18
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Long-Term Assets |
1
|
1
|
1
|
0
|
4
|
3
|
|
| Total Assets |
31
N/A
|
30
-3%
|
54
+82%
|
60
+11%
|
57
-5%
|
44
-23%
|
|
| Liabilities | |||||||
| Accounts Payable |
3
|
3
|
3
|
5
|
5
|
5
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
6
|
0
|
|
| Other Current Liabilities |
1
|
1
|
1
|
1
|
0
|
0
|
|
| Total Current Liabilities |
4
|
4
|
4
|
6
|
11
|
5
|
|
| Long-Term Debt |
13
|
14
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
9
|
8
|
10
|
12
|
16
|
8
|
|
| Total Liabilities |
26
N/A
|
26
+1%
|
13
-49%
|
18
+36%
|
27
+48%
|
13
-52%
|
|
| Equity | |||||||
| Common Stock |
0
|
0
|
9
|
9
|
9
|
9
|
|
| Retained Earnings |
2
|
3
|
4
|
1
|
13
|
12
|
|
| Additional Paid In Capital |
7
|
7
|
36
|
35
|
35
|
35
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
5
N/A
|
3
-25%
|
41
+1 077%
|
42
+2%
|
30
-28%
|
31
+3%
|
|
| Total Liabilities & Equity |
31
N/A
|
30
-3%
|
54
+82%
|
60
+11%
|
57
-5%
|
44
-23%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
9
|
9
|
9
|
8
|
8
|
8
|
|
Switch to:
Switch to:
See Also
Discover More
